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Abstract
Background: Irisin, a recently identified myokine/adipokine, has potential role in type 2 diabetes and obesity.
Normal weight obesity (NWO) is associated with a significantly higher risk of developing metabolic syndrome
and cardiometabolic dysfunction. The aim of this study was to investigate association of irisin level with NWO,
glycemicand lipid profile in women.
Methods: In this matchedcase-control study, 38 subjects with NWO (body mass index (BMI) <25 kg/m2 and
BF % > 30) as case and 26 controls (BMI <25 kg/m2 and BF % < 30) were selected randomly from sport clubs in
the East area of Tehran, Iran. In addition to anthropometric variables, including BMI and body composition, fasting
blood sugar (FBS), fasting levels of irisin andinsulin, triglyceride (TG), total cholesterol (TC), high-density lipoprotein
(HDL) and low-density lipoprotein (LDL) cholesterol were measured. All statistical analyses were performed with
SPSS 18.0.
Results: In univariate analysis, levels of irisin were significantly higher in subjects with NWO compared to controls
(0.81 ± 0.41vs. 0.58 ± 0.26 ng/ml, P = 0.009). This association remained significant after adjusting for confounders
(adjusted for energy intake, physical activity, waist circumference and BMI) (P = 0.049). In NWO, irisin level was not
significantly correlated with all glycemic and lipid profile. In control group, only correlation ofirisin with insulin was
statistically significant (P = 0.03).
Conclusion: Serum irisin levels were higher in NWO subjects than controls. In control group, only the negative
association between irisin and insulin levels was statistically significant.
Further studies with larger sample size are clearly needed to evaluate the potential role of irisin in NWO subject and
other disturbed metabolic conditions.
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Background
Normal weight obesity (NWO) is defined as a condition
that is characterized by normal body mass index (BMI:
18.5–24.9 kg/m2) with increased percent body fat. Recent
investigations have reported the association of NWO
with cardiovascular risk factors, and also with increased
mortality in women [1]. However, the exact prevalence
of NWO in the general population is unknown.
The prevalence rates ofhigh waist circumference, waist
to hip ratio, high serum levels of low-density lipoprotein
(LDL) and triglycerides, low serum level of high-density
lipoprotein (HDL), reduce insulin sensitivity (measured
as HOMA-IR) and high C-reactive protein levels were
higher in patients with NWO compared to subjects with
normal weight and normal body fat mass [2].
Increasing evidence suggests that skeletal muscle is an
endocrine organ, producing and releasing cytokines which
have been termed “myokines” [3, 4]. Several of these
myokines are involved in the regulation of physiological
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functions and metabolic pathways, including body me-
tabolism and energy homeostasis [4, 5].
Irisin is a newly discovered plasma myokine/adipokine
that is produced by the proteolytic cleavage of fibronec-
tin type III domain containing 5 (FNDC5). In skeletal
muscle, the peroxisome proliferator-activated receptor γ
(PPAR- γ) coactivator 1α (PGC-1α) expression as a
mediator of the effects of exercise, stimulates increased ex-
pression of FNDC5 as a precursor of irisin [6]. In addition
to the myocytes, irisin is expressed in adipocytes, kidney,
lungand liver tissues. However, the maximum expression
of irisin was observed in skeletal muscles [7].
However, conflicting data on the role of irisin or
FNDC5, as the precursor of irisin, in obesity and glucose
metabolism have recently emerged. Some studies ob-
served the increased blood concentration of irisin and
FNDC5 expression in obese patients [8, 9]. In contrast,
other studies have shown opposite results [7, 10]. While
some researchers found the negative relationship between
bloodirisin level and glycemic parameters [11], others re-
ported that irisin levels positively correlated with the serum
concentration of insulin, insulin resistance and fasting
blood glucose [12]. In addition, irisin levels were signifi-
cantly inversely associated with the onset of type 2 diabetes
[13, 14] and with another pathway, such as inflammation
and oxidative stress, which have previously been proposed
to be involved in insulin resistance [15].
However, to our knowledge, no study to date has exam-
ined the relation between blood irisin levels in patients
with the normal weight obesity. Therefore, we aimed to
investigate association between irisin levelwithNWO,
glycemic and lipid profile in women.
Methods
Subjects
This matched case–control study that performed from
October 2014 to May 2015, women aged 19 to 39 years
were selected randomly from sport clubs in the East area
of Tehran, Iran. The study groups included 38 subjects
with NWOand 26 healthy subjects as a control group. Two
groups were frequency matched based on age groups.
Normal weight obesity was defined as those subjects
with a normal body mass index (BMI 18.5–24.9 kg/m2)
and high body fat percentage (%BF) content (BF >
30 %). Subjects with normal BMI (18.5–24.9 kg/m2)
and %BF content < 30 % of body weight were considered
as controls. The age and BMI were matched between two
groups.
Sample size was calculated based on a pilot study and
according to two mean comparison formula .subject
were selected by announcements in the youth sports
club in Tehran among them, women aged 19–39 years
with normal weight for height who had joined the club
recently were selected to measure body composition
using the BIA (bio electric impedance analyzer).
Subjects were excluded if they had a history of diabetes,
liver and kidney dysfunction, hypertension, gastrointes-
tinal, cardiovascular, thyroid and autoimmune diseases or
diagnose infection. Pregnant and lactating individuals were
not included andsubjects who used any drugs, supple-
ments or diet for a long time and professional athletes
were also excluded from the study.
Ethics statement
This study was approved by the ethics committee of
Endocrinology and Metabolism Clinical Sciences Institute,
Tehran University of Medical Sciences (No: 1393-01-98-
1778). All procedures were inaccordance with institutional
guidelines and were carried out in compliance with the
HelsinkiDeclaration. Before the collection of data, all par-
ticipants completed written informed consent form.
Measurements of biochemical parameters
Blood samples were collected after 10–12 h fasting and
serum and plasma were separated. All of the samples
were stored at −80 °C for later biochemical analysis. Fasting
serum levels of glucose and lipid profiles, including total
cholesterol (TC), triglyceride (TG) and high density
lipoprotein (HDL-C) were measured by a Hitachi 912-
autoanalyser (Hitachi, Mannheim, Germany) using
commercial kits. Low density lipoprotein (LDL) was
calculated by friedewald equation. Insulin was measured
by radioimmunoassay. Serum irisin concentration was
measured using the enzyme-linked immunosorbent assay
(ELISA) kits (Biovendor Laboratory Medicine, Modrice,
Czech Republic).
Body composition measurements
After removal shoes and heavy clothing, weight and height
were measured using a Seca scale (Seca725 GmbH & Co.
Hamburg, Germany), to the nearest 0.1 cm and 0.1 kg,
respectively for each participant. BMIwas calculated as
weight (in kg) the square of height in meters. Waist cir-
cumference was measured by a plastic tape measure locat-
ing above the uppermost lateral border of the right ilium,
at the end of a normal expiration, to the nearest 0.1 cm in
a horizontal plane. Hip circumference was measured by
placing the tape around the hips at the biggest circumfer-
ence of the buttocks using non-stretchable tape measures.
Body composition, including total body fat mass and fat-
free mass were assessed using Tanitabody composition
analyzer (Model TBF-300; Tanita, Tokyo, Japan) during
fasting state and before blood sampling. Subjects were
required to remove all metal objects, such as earrings,
etc., and to wear light clothing before each measure-
ment. The device calculates body fat percentage, fat
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mass, and fat free mass and predicts muscle mass on
the basis of data using BIA.
Statistical analysis
The normal distribution assumption of continuous
variables was assessed using Shapiro-wilk test. Data
was expressed as mean ± SD. The analysis ofcovariance
(ANCOVA) test was used tocompare mean of irisin
level between NWO and controls after adjustment for
confounders in threedifferent models. In model I crude as-
sociation was assessed. In model II energy intake, physical
activity, waist circumference (WC) was adjustedand in
model III additionally BMI was adjusted. Spearman correl-
ation coefficients were used to determine the relationship
between irisin levels and glycemic and lipid profile. All
statistical analyses were performed using SPSS version 18
(SPSS Inc., Chicago, IL). The level of significance was
considered as ≤0.05.
Results
Clinical and laboratory findings and demographic char-
acteristics of the study groups are presented in Table 1.
The mean age of subjects were participated in this study
was 28.95 ± 4.63 years, which was not significantly differ-
ent between NWO and control groups.
The mean ± SD for weight, waist and hip circumfer-
ences and BF% were higher significantly in subjects with
NWO compared to controls.
The results showed that thelevelof LDL, TG, FBS and
insulin in subjects with NWO were higher than control
subjects which was statistically significant for fasting
levels of insulin and glucose.
Table 2 shows the crude and adjusted mean levels of
irisin in NWO and control groups. In crude model cir-
culating irisin levels were significantly higher in sub-
jects with NWO compared with controls (0.81 ± 0.41vs
0.58 ± 0.26 ng/ml, P = 0.009). This association remained
significant after adjusting for potential confounders in
model II (P = 0.02) and III (P = 0.049).
The correlation between circulating irisin levels and
biochemical variables are shown in Table 3. In NWO,
irisin level was not significantly correlated with all gly-
cemic and lipid profile. In control group, only correlation
of irisin with insulin was statistically significant (P = 0.03).
Discussion
The current findings indicated the significantly higher
circulating levelof irisinin NWO subjects compared to
controls who had normal weight and normal BF%. How-
ever, previous trials reported the increased blood level of
irisin in the obese subjects. In this context, Saleh et
al.found significantly increased irisin level in obese ando-
verweight women compared to normal weight ones [16].
Similarly, the reports of Ivanov et al. [17], Stengel et
al. [10], and Wen et al.[18] showed the positive associ-
ation between irisin levels and BMI in healthy non-
diabetic subjects. The results of Stengle et al. [10] and
Huh et al. [7] studies indicated that circulating levels of
irisin were higher in healthy subjects with morbid obes-
ity than normal weight controls. On the other hand, Liu
et al. reported that circulating irisin level had a negative
association with BMI, waist to hip ratio and BF% in men
[13]. However in this study, body composition was not
measured directly.
It has been suggested that BF% is a better indicator
oftotal adiposity compared to BMI. In support of this
statement, our results showed that in NWO subject who
Table 1 Baseline anthropometric, clinical and laboratory
characteristics of normal weight obese (NWO) subjects and
healthy controls
Variables NWO (n = 38) Controls (n = 26) P-value
Age (year) 28.76 ± 4.67 29.23 ± 4.50 0.69
Height (cm) 165.89 ± 4.43 165.32 ± 4.81 0.62
Weight (kg) 62.77 ± 4.77 56.98 ± 4.40 <0.0001
BMI (kg/m2) 22.26 ± 1.23 20.88 ± 1.28 <0.0001
Waist circumference (cm) 74.77 ± 4.74 70.84 ± 3.03 <0.0001
Hip circumference (cm) 98.90 ± 4.29 93.44 ± 2.99 <0.0001
WHR 0.75 ± 0.04 0.77 ± 0.03 0.66
Body fat (%) 32.66 ± 2.47 23.79 ± 1.62 <0.0001
Body fat (kg) 20.47 ± 2.71 13.56 ± 1.45 <0.0001
DBP (mmHg) 70.66 ± 13.6 75.50 ± 12.9 0.57
SBP (mmHg) 90.76 ± 12.6 91.5 ± 17.1 0.11
Total cholesterol (mg/dl) 174.00 ± 29.35 174.1 ± 21.44 0.97
LDL- cholesterol (mg/dl) 90.89 ± 18.08 89.53 ± 17.07 0.76
HDL- cholesterol (mg/dl) 59.02 ± 13.70 61.11 ± 9.00 0.46
TG (mg/dl) 87.07 ± 28.28 82.92 ± 26.67 0.55
FBS (mg/dl) 87.71 ± 8.16 84.5 ± 7.3 <0.0001
Insulin (μIU/ml) 9.02 ± 4.75 6.31 ± 2.49 <0.0001
Data are expressed as mean ± SD
P < 0.05 is statistically significant
NWO normal weight obesity, BMI body mass index, WHR waist to hip ratio,
DBP diastolic blood pressure, SBP systolic blood pressure, LDL low density
lipoprotein, HDL high-density lipoprotein, TG triglyceride
Table 2 Serum level of irisin in subjects with normal weight
obesity (NWO) compared to controls
Circulating irisin level (ng/ml) NWO (n = 38) Controls (n = 26) P-value*
Model 1 0.81 ± 0.41 0.58 ± 0.26 0.009
Model 2 0.81 ± 0.36 0.59 ± 0.35 0.02
Model 3 0.82 ± 0.36 0.58 ± 0.40 0.049
Model 1: No adjustment
Model 2: adjusted for energy intake, physical activity, waist circumference
Model 3: adjusted for energy intake, physical activity, waist circumference
and BMI
*P-value is for ANCOVA test, P < 0.05 is statistically significant
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had normal range of BMI and higher BF%, the serum
level of irisin was significantly higher than controls.
Regarding to possible mechanism, it is suggested that
increased circulating irisin in obesity is an adaptive com-
pensatory response to obesity-induced disturbed metab-
olism such as decreased insulin level [16]. Alternatively,”
irisin resistance” may be another description for increased
levels of irisin in obesity, as has already established for
leptin or insulin in obesity [11].
According to our observation in this study, serum iri-
sin levelcorrelated positively with FBS and insulin levels
in NWO subjects. This correlation was negative in con-
trols, although it was only significant between irisin and
insulin level in controls.
Gomer et al. reported positive correlation between irisin
level and HbA1c in T2D patients with and without obesity
[19]. Liu et al. showed the positive association between cir-
culating irisin and FBS in non-obese, non-diabetic individ-
uals [13]. In consistence to this results, Huh et al., Stengel
et al. and Liu et al. showed positive correlation between
serum levels of irisin and FBS [7, 10, 13]. Data from our
study showed that the serum levels of FBS and insulin
were higher significantly in NWO patients compared to
controls. Another study speculated that long time expos-
ure to high blood glucose, irrespective of BMI, was associ-
ated significantly with decreased serum level of irisin in
diabetic patients [7, 13]. Contrary to type 2 diabetes and
despite to higher level of FBS and insulin, NWO patients
had higher levels of irisin. Patients with NWO are sus-
ceptible to development of T2D; therefore, it is possible
that the irisin levels could be decreased in long-time in
NWO subjects. In addition, the high serum level of irisin
in NWO subjects might be compensatory response to
condition called “irisin resistance”, similar to T2 DM.
In agreement with this result, our study showed that
the adipose tissue might be the main source of irisin se-
cretion in NWO subjects, because NWO subjects had a
higher BF% than controls.
Previous studies found that the activity oftranscrip-
tional co-activator PPAR-γ co-activator-1 α (PGC1α), a
molecule up-stream of irisin, in skeletal muscles and
therefore circulating irisin level was lower in patients
with type 2 diabetes or pre-diabetes than healthy obese
subjects [20–22].
On the other hand, in patients with abnormal blood
glucose or T2DM, the expressions of FNDC5/irisin are
decreased in adipose tissue and skeletal muscles.
Saleh et al. suggested that the glucose intolerance may
gradually up regulate the skeletal muscles expression of
FNDC5/irisin in non-diabetic subjects [23]. According
to this statement and despite to the results of previous
studies, we expect the high circulating irisin level in pa-
tients with T2DM who are exposed to high level of glucose.
To illustrate this conflict observation, we mentioned the
results of other studies suggested timelyregulation of local
and circulating irisin with tissue-specific mechanisms in
different physiological status such as obesity, pre-diabetes
and T2DM [24, 25]. Also, Choi et al. and Huh et al.
showed that decreased blood irisin level could expose sub-
jects to the development of insulin resistance and T2DM
[7, 14]. Similar to the results of Saleh et al., study, we found
that serum irisin was significantly negatively associated
with insulin level in control subjects [16].
Interestingly, it was shown the opposite expression of
FNDC5 in skeletal muscle and adipose tissue of T2D pa-
tients compared to lean, obese and pre-diabetic subjects
[26]. Diabetic patients displayed the lowest expression of
FNDC5 in adipose tissue and circulating irisin level. The
muscle expression of FNDC5 was similar in diabetic pa-
tients and obese subjects. It is suggested that glucose
and lipid, not insulin might be inhibitory regulatory fac-
tor in muscle FNDC5 expression in metabolic disorders.
It is plausible to think that different interaction exist
between expressions of FNDC5 in skeletal muscle and
adipose tissue in patients with NWO who had increased
insulin and glucose levels. In addition, this expression
might change during long term dependant to the glycemic
control in NWO subjects.
Our current data also revealed a positive correlation
between irisin and HDL-c, LDL-c, TG and a negative
correlation association between irisin and TC in NWO
subjects. In addition, our results indicate that circulating
irisin correlated positively with HDL-c and TCand corre-
lated negatively with LDL-c and TG in control group.
A limited study was performed to evaluate the associ-
ation between irisin and lipid profile in various popula-
tions with obesity or diabetes and both of them. Liu et al.
reported that serum level of irisin correlated positively
with total cholesterol and TG in non- obese, non- diabetic
subjects [13]. The significant association between irisin
and HDL-c in healthy non-diabetic subjects in Benton et
al. study, suggested a protective role for circulating irisin
in cardiovascular disease [27], which is similar to our re-
sult in NWO and controls. Another study conducted by
Table 3 Spearman’s correlation coefficients between serum
level of irisin and glycemia/ lipid profile in normal weight obese
(NWO) subjects and controls
Variables NWO (n = 38) Controls (n = 26)
r P-value* r P-value*
Total cholesterol (mg/dl) - 0.02 0.89 0.28 0.15
LDL- cholesterol (mg/dl) 0.001 0.99 −0.23 0.25
HDL- cholesterol (mg/dl) 0.06 0.68 0.05 0.78
TG (mg/dl) 0.11 0.48 −0.06 0.75
FBS (mg/dl) 0.06 0.69 −0.08 0.74
Insulin (μIU/ml) 0.13 0.4 −0.42 0.03
*P-value is for spearman correlation, P < 0.05 is statistically significant
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Sanchis-Gomer et al., reveals no significant relationship
between irisin and TC, TG and LDL [28]. In contrary,
Wen et al. study showed a significantpositive correlations
of TC, TG and LDL with circulating irisin in non- diabetic
participants [18]. The positive association between serum
level of irisin and TG was shown in Liu et al. study [13].
Previous studies showed that muscle FNDC5 was posi-
tively associated with TG [7], and negatively associated
with HDL-c [7, 12]. For the first time, Saleh et al. reported
that serum irisin has a positive relationship with both lep-
tin and insulin in type 2 diabetes [16]. It is plausible to
think that the association between irisin and lipid profile
may be mediated by its effect on leptin.
The correlation of irisin with TG, LDL-c and HDL-c
was inversely between NWO and control subjects. More
studies are needed to establish the detail association
between irisin and lipid profiles in subjects with NWO
compared to obese, diabetes and non- obese, non-diabetic
healthy subjects. In addition to skeletal muscles and
adipose tissue, FNDC5 mRNA/irisin detected in various
tissues, including pericardium, kidney, liver, lung and
neurons in human [7, 9, 29–31]. It was suggested
thatthe muscle/adipose irisin secretion ratio might vary
dependent to the physiological status. In athletes with
trained muscles by exercise, muscle tissue would actively
increase FNDC5/irisin but, in obesity, the adipose tissue is
the main source of FNDC5/ irisin secretion [32].
The limitations of our study are its small sample size
and lack of information about the FNDC5 expression
and irisin level in adipose tissue, skeletal muscles and its
ratio in subjects with normal weight obesity. There was
no data about the life quality and socioeconomic factors
in our study that considered as a limitation of our study.
The strength of our study is that this is the first study
that investigated blood irisin level and its association
with biochemical parameters in subjects with normal
weight obesity.
Conclusion
In summary, the results of this study demonstrated-
serum irisin levels were higher in NWO subjects than
controls. In control group, only the negative association
between irisin and insulin levels was statistically signifi-
cant. Further studies with larger sample size are clearly
needed to evaluate the potential role of irisin in NWO
subject and other disturbed metabolic conditions.
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